Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSIn a Melbourne study, 75 percent of people who had never met H5N1 already carried T cells that recognized it, because seasonal H1N1 and bird-flu hemagglutinin share a conserved stalk. The catch: the primed cells likely soften an infection rather than prevent one, and an H3N2-heavy immune history barely helps.
At least six reports since 2025 describe lithium climbing after patients on stable doses started a GLP-1 drug, and Europe has opened a safety signal. A new analysis says the acute spikes make sense, but a sustained per-dose rise does not.
A controlled rat study made surgically repaired Achilles tendons stronger and better organized with TB-500, saw no significant gain from BPC-157 on its own, and found the popular two-peptide stack beat neither peptide alone.
A pooled analysis of four randomized trials found tesamorelin reliably shrinks the deep abdominal fat that antiretroviral therapy can add, and raises lean mass. The endpoints are body measures, not health outcomes, and the discontinuation rate ran more than twice as high.
A 96,356-patient meta-analysis found every 90-day complication rate lower in GLP-1 users before hip and knee replacement, with hips carrying most of the benefit. The evidence is graded very low, and the all-favorable pattern is also the fingerprint of who gets the drug.
Neuropeptide Y stuck to graphene oxide and injected into the amygdala suppressed a conditioned fear response in rats, acting through specific receptor-bearing synapses rather than sedating the region. It is a delivery proof of concept in animals, with a strong framing on a freezing assay.
The first pooled analysis of GLP-1 exposure around conception found no change in the risk of high blood pressure in pregnancy (odds ratio 0.91). It rests on three US observational cohorts that disagreed with each other, so it rules out a large effect, not a small one.
In 31 obese patients, adding tirzepatide to standard biologic therapy improved symptoms, function, and skin over six months. Whether that is the drug treating the arthritis or just the weight coming off is the open question.
Kisspeptin, the peptide that switches on puberty, throttled a RAS-driven cancer in the lab by cutting one downstream link (SP1 to N-cadherin) instead of drugging the mutated gene itself. It is a bench mechanism, not a treatment, but it hands the next lab a specific arrow to test.
In a records study of 7,304 matched patients with idiopathic intracranial hypertension, GLP-1 users had about half the later cognitive decline. Every outcome favored the drug, which is also what confounding by healthier, lighter patients would look like.
Approved RAS drugs target a single mutation and tumors escape by reactivating the rest. LUNA18, an oral cyclic peptide from Chugai, blocked the whole RAS family in the lab, including the wild-type back channel. The work is still preclinical.
A target trial emulation across roughly 390,000 matched diabetes patients found no melanoma link for GLP-1 receptor agonists, and the one borderline non-melanoma bump dissolved under a bias-correction check.
In rats and mice, switching on calcitonin receptors in a brainstem cluster called the locus coeruleus cut food intake and body weight while leaving nausea and heart rate untouched. The body's own amylin and CGRP act there too, a hint for the amylin drugs chasing weight loss with fewer side effects.
In a phase 2 trial, 50 people seeking help for alcohol use disorder took oral semaglutide or placebo for eight weeks. The drug did not beat placebo on a lab craving test, but it cut heavy drinking days, real-world craving, alcohol-related harms, and even cannabis use.
Peceleganan, an approved antimicrobial peptide built from moth and bee-venom fragments, beat placebo on the clinical scoring of infected diabetic foot ulcers in a double-blind trial. Overall it did not clear measurably more bacteria. The one exception was the drug-resistant subgroup.